Literature DB >> 11978635

Fas/Fas ligand interactions play an essential role in the initiation of murine autoimmune diabetes.

Maki Nakayama1, Masao Nagata, Hisafumi Yasuda, Kenji Arisawa, Reiko Kotani, Katsumi Yamada, Shahead Ali Chowdhury, Sagarika Chakrabarty, Zhen Zi Jin, Hideo Yagita, Koichi Yokono, Masato Kasuga.   

Abstract

Apoptosis via Fas/Fas ligand (FasL) interactions has been proposed to be a major T-cell-mediated effector mechanism in autoimmune diabetes. To elucidate the role of Fas/FasL interactions in NOD diabetes, the effects of neutralizing anti-FasL antibody on autoimmune responses were evaluated. Islet-specific CD8(+) and CD4(+) T-cells expressed FasL upon activation and mediated FasL-dependent cytotoxicity against Fas-expressing target cells in vitro, although their cytotoxicity against islet cells was not blocked by anti-FasL antibody. Moreover, administration of anti-FasL antibody failed to inhibit diabetes in vivo in the CD8(+) T-cell adoptive transfer model. On the other hand, blockade of Fas/FasL interactions significantly inhibited CD4(+) T-cell-dependent diabetes in adoptive transfer models. These results suggest a substantial contribution of Fas/FasL interactions to CD4(+), but not CD8(+), T-cell-mediated destruction of pancreatic beta-cells. When anti-FasL antibody was administered to NOD mice between 5 and 15 weeks of age, the onset of diabetes was slightly delayed but the incidence was not decreased. However, administration of anti-FasL antibody at 2-4 weeks of age completely prevented insulitis and diabetes. These results suggest that Fas/FasL interactions contribute to CD4(+) T-cell-mediated beta-cell destruction and play an essential role in the initiation of autoimmune NOD diabetes.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11978635     DOI: 10.2337/diabetes.51.5.1391

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  13 in total

1.  Inhibition of Fas ligand in NOD mice unmasks a protective role for IL-10 against insulitis development.

Authors:  Zuoxiang Xiao; Abdiaziz S Mohamood; Sophia Uddin; Rachel Gutfreund; Chiaki Nakata; Andrew Marshall; Hiroaki Kimura; Patrizio Caturegli; Karl L Womer; Yanfei Huang; Chunfa Jie; Shukti Chakravarti; Jonathan P Schneck; Hideo Yagita; Abdel Rahim A Hamad
Journal:  Am J Pathol       Date:  2011-06-15       Impact factor: 4.307

2.  In vivo diabetogenic action of CD4+ T lymphocytes requires Fas expression and is independent of IL-1 and IL-18.

Authors:  Li Wen; Elizabeth A Green; Thomas Stratmann; Anaïs Panosa; Ramon Gomis; Elizabeth E Eynon; Richard A Flavell; Jovita A Mezquita; Conchi Mora
Journal:  Eur J Immunol       Date:  2011-04-13       Impact factor: 5.532

3.  Non-viral systemic delivery of Fas siRNA suppresses cyclophosphamide-induced diabetes in NOD mice.

Authors:  Ji Hoon Jeong; Sun Hwa Kim; Minhyung Lee; Won Jong Kim; Tae Gwan Park; Kyung Soo Ko; Sung Wan Kim
Journal:  J Control Release       Date:  2010-01-18       Impact factor: 9.776

4.  Apoptosis in autoimmune diabetes: the fate of beta-cells in the cleft between life and death.

Authors:  Charles Sia; Arno Hänninen
Journal:  Rev Diabet Stud       Date:  2006-05-10

5.  Critical roles of CD30/CD30L interactions in murine autoimmune diabetes.

Authors:  S Chakrabarty; M Nagata; H Yasuda; L Wen; M Nakayama; S A Chowdhury; K Yamada; Z Jin; R Kotani; H Moriyama; O Shimozato; H Yagita; K Yokono
Journal:  Clin Exp Immunol       Date:  2003-09       Impact factor: 4.330

Review 6.  Cellular FLICE-inhibitory protein: an attractive therapeutic target?

Authors:  Olivier Micheau
Journal:  Expert Opin Ther Targets       Date:  2003-08       Impact factor: 6.902

Review 7.  Analysis of gene profile, steady state proliferation and apoptosis of double-negative T cells in the periphery and gut epithelium provides new insights into the biological functions of the Fas pathway.

Authors:  Abdel Rahim A Hamad
Journal:  Immunol Res       Date:  2010-07       Impact factor: 2.829

Review 8.  B cell-targeted immunotherapy for type 1 diabetes: What can make it work?

Authors:  Abdel Rahim A Hamad; Rizwan Ahmed; Thomas Donner; Georgia Fousteri
Journal:  Discov Med       Date:  2016-03       Impact factor: 2.970

9.  Histopathology of type 1 diabetes: old paradigms and new insights.

Authors:  Ken T Coppieters; Matthias G von Herrath
Journal:  Rev Diabet Stud       Date:  2009-08-10

10.  Contribution of Fas to diabetes development.

Authors:  Alexei Y Savinov; Andrew Tcherepanov; E Allison Green; Richard A Flavell; Alexander V Chervonsky
Journal:  Proc Natl Acad Sci U S A       Date:  2003-01-13       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.